Articles related to LUNG CANCER

The study included 186 patients who had recently been diagnosed with advanced lung cancer (Stage IV). Investigators were curious about the relationship between depression levels and systemic inflammation ratio (SIR) biomarker levels at diagnosis. SIRs are made up of three biomarkers that are linked to inflammation in the body, which has been linked to lower survival rates. All participants also filled out a depression questionnaire. According to the findings, 35% of patients had moderate to severe depressive symptoms.

Charu Aggarwal, MD, MPH, of the University of Pennsylvania’s Abramson Cancer Center in Philadelphia, H. Jack West, MD, of the City of Hope Comprehensive Cancer Center in the Los Angeles area, and Devika Das, MD, of the University of Alabama at Birmingham discuss the distinction between uncommon EGFR mutations and sensitizing mutations, as well as the lack of data on how to treat these patients with tyrosine kinase inhibitors.

Medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs who treat patients with lung cancer should be better able to describe ideal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC and evaluate clinical trial data of emerging immunotherapy-based agents in the treatment after completing this three-chapter, 0.50-credit CME activity.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

Spectrum Pharmaceuticals would need to study the drug further, including generating data from a randomized controlled trial, according to the release. Spectrum responded by stating that it would “de-prioritize poziotinib program activities, effective immediately.” The decision comes after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the drug’s demonstrated clinical benefit did not outweigh its risks.

A review of the seven zones/14 stations as defined by the International Association for the Study of Lung Cancer (IASLC): Supraclavicular zone Station 1 (left/right): low cervical, supraclavicular, and sternal notch nodes Upper zone (superior mediastinal nodes) Station 2 (left/right): upper paratracheal nodes Station 3A and 3P: pre-vascular and retrotracheal nodes Station 4 (left/right): lower paratracheal nodes Aortopulmonary zone Station 5: subaortic nodes (aortopulmonary window) Station 6: para-aortic nodes, ascending aorta or phrenic Subcarinal zone Station 7: subcarinal nodes Lower zone (inferior mediastinal nodes) Station 8 (left/right): para-esophageal nodes (below carina) Station 9 (left/right): pulmonary ligament nodes Hilar and interlobar zone (pulmonary nodes) Station 10 (left/right): hilar nodes Station 11: interlobar nodes Peripheral zone (pulmonary nodes) Station 12: lobar nodes Station 13: segmental nodes Station 14: subsegmental nodes